ru-band lu, md. shiou-lan chen, phd. national cheng kung university neuro-degeneration and novel...
TRANSCRIPT
Ru-Band Lu, MD.Shiou-Lan Chen, PhD.
National Cheng Kung University
Neuro-degeneration and
Novel Treatment in Heroin dependence
Neurodegeneration in Mental Illnesses
• Schizophrenia
• Bipolar disorders
• Substance use disorders (alcohol)
• Anxiety disorders?
• Personality disorders?
2
Neuronal degeneration in schizophrenia
Schizophrenia and bipolar disorders
– Decreased gray & white matter and lateral ventricular dilatation (Largen et al., 1984; De Peri l et al., 2012)
3
Neuronal degeneration in Bipolar Disorder (BP)
• Diffused gray and white matter loss, enlarged ventricles & mild prefrontal volume loss. (Wilde, et al., 1985)
• 17% larger lateral ventricles and 2.5 times in deep white matter hyperintensities. (Kempton, M.J., et al., 2008.)
4
MRI in middle-aged women
Neuronal degeneration in Substance Abuse
5
Neuronal degeneration in substance use?
Animal studies
•Opioid use – Reduction dopaminergic neurons in ventral tegmental area (VTA) of rats (Chu, 2008)
•Heroin and cocaine use– Showing neurotoxicity in rat (Cunha-Oliveira et al., 2010)
•Alcohol use– Reduced hippocampal neurogenesis
– Impaired long-lasting memory in monkey (Taffe, 2010).
6
Treatment of Neurodegeneration disease
• Current therapy treating symptoms, but few slowing or inhibiting the progress
• Without treatment in heroin dependence
• Development of novel therapy for central, peripheral degeneration illness
7
Microglia
Source for
neurotrophin production
Target for
anti-inflammation
Astroglia
Glial cells : Key roles in disease and prime targets for therapy
8
9
Hypothesis
1.Neuronal
Degeneration
2.White/Gray Matter Damage
Causing/Onset/Relapse of Mental Illness
The activation of Neuro-immune system
BrainBlood
Blood-Brain-Barrier
CytokinesCytokines
Qin et al. (2007)
0
20
40
60
80
100
120
0 .5h 1h 2h 3h 6h 9h 7 m 10 m
TN
F
(%
of
pea
k)
Time
A single IP LPS injection induced TNF-α production both in peripheral and brain in rat
Liver**** **
**
**
**
Brain** **
**** ****
**
**
Blood**
**
**
**
TNF-
LPS
Kupffer cell
Role of microglia in toxin-induced progressive neurotoxicity
Pro-inflammatory
Factors (ROS, NO., TNFa, IL-1,
PGs)
Reactive Microgliosis
(Self-propelling)
LPS (Extra Neurotoxin)
Ac
tiva
tio
n
MPTP (Intra Neurotoxin)
Microglia
(Working Model)
Dopaminergic
Neuronal Damage
11(Hong et al., 2005)
NADPH oxidase (PHOX)
Activated
O2O2 • –
NADPH NADP+ + H +
Resting
gp91
p22rap1a
p40
p47rac2
p67
MAC-1
LPS
out
in
PKC
P
P
Naloxone,Dextromethorphan
Memantine
12(Hong et al., 2005)
Transfection of gp91PHOX, a membrane subunit of PHOX,
increases [3H]-naloxone binding
0
100
200
300
[3H]-(-)-Nal
Bin
din
g C
ap
acit
y (
% W
T)
WT
[3H]-(+)-Nal
*
Gp91-transfected
400COS-7 Cells (WT)
Ligand Binding Assay
StableTransfectio
n
COS-7 gp91
(gp91)
gp91
*
13(Hong et al., 2007)
O2
O2 • –
Dual Functions of Superoxide Radicals
gp91
Microglia
MAC1
TLR4LBP
CD14
PHOX
ROS
H2O2
O2 • –
TNF- IL-1
NO •
ONOO -
2) Gene Expression
1) Neurotoxicity
NF-kB,AP-1
PKCLPS
LPS
DA neurons 14(Hong et al., 2005)
15
Memantine
• An non-comparative NMDA receptor, medication for Alzheimer's disease (20 mg/day)
• Low dosage having neuroprotective effects in vitro and in vivo (Wu et al., 2009)
LPS
Microglia
TNF-aIL-1b
Neuronal death
ONOO-
NO • O2 • -
Conventional Regimen:
• Aspirin, COX 2 inhibitors (PG)
• Anti-oxidants (Free radicals)
• Antibodies (TNF-α, IL-1)
• Receptor antagonists (TNF-α)
• Cortisone (toxic for long-term use)
Novel Strategy: Modulation of microglial activity
•Morphinans : Naloxone, D-Morphine
Dextromethorphan
•Dynorphins, Enkephalin, PACAP
•Memantine
Novel anti-inflammatory therapy
PG’s
16
(Hong et al., 2005)
Memantine
LPS
Dopaminergic Neuron
ONOO-
TNFαIL-1β
NO O2 • -
Microglia
PHOX
Inhibition of microglial PHOX (by binding to gp 91) is
associated with DM-, Memantine-elicited neuroprotective effect
17(wu et al., 2009)
18
Mechanism underlying Memantine induced increase in expression of neurotrophic factors in astroglia
HDACHATs
Astroglia
Memantine
mRNA of GDNF, BDNF
GDNF, BDNF
Nuclear
(Chen et al., 2009)
LPS
Acti
vati
on
Trophic factors:(GDNF, BDNF, NGF)
Pro-inflammatory factors: Superoxide, iROS NO, TNF, PGE2
Reactive Microgliosis
Astroglia
Microglia
DA neuron
Inhibition
Memantine
Stimulation
Memantine
Combined therapy for neurodegenerative diseases
(Self-propelling)
Neurogenesis
19(wu et al., 2009)
Hypotheses & Experimental Protocol in Human
• Neuro-inflammation inducing heroin dependence and progressive neurodegeneration
• Heroin dependence and neurondegeneration causing progression of heroin use, mental illness
20
Cytokines v.s. Substance Use in Animal
• Opioid
– Increased IL-1β, and IL-6 in vitro. (Kapasi, 2000) – Increased iNOS and cytokines in the locus coeruleus (Dyuizen I et al., 2009)
• Alcohol – Increased microglia in cerebellar and hippocampal of the rat . (Riikonen, 2002)
– Downregulated in the neocortex, hippocampus, and cerebellum of rats and conversed by COX-2. (Pascual et al., 2007)
• Methamphetamine – Increased free radical & overactivity of cytokines. (Imam, 2001)
21
Research Aims
• Analysis of plasma cytokine and BDNF levels– Cytokines and BDNF: through BBB (Pan et al., 1998)
– BDNF: a neuro-degeneration biomarker (Laske et al. 2006)
– Cytokines: an neuro-inflammation biomarker (Buckley, 2007)
• The relationship of plasma cytokine, BDNF levels with heroin dependence
• Using effective drugs in neuroprotective and neurogenesis
22
23
Human-
Heroin dependence treatment
Methods
• Methadone maintaining treatment
• Adjustment the methadone dosage
• Memantine (5mg/day) or placebo
• Measuring methadone plasma level weekly
• Measuring BDNF, cytokines (pre- & post-treatment)
24(Chen et al., submitted 2013)
Results
• Longer of years of heroin use ( 5 years, n = 57 or 6 years, n = 58)
– lower TGF-β1 and BDNF levels
– Higher MTD (methadone) dosage
• Compared to healthy controls at baseline
– Higher plasma TNF-, CRP, IL-1β, IL-6, and IL-8 levels
– Lower plasma TGF-β1 and BDNF levels25
(Chen et al., submitted, 2013)
Correlation of heroin used period with plasma
MTD dose, cytokines and BDNFat baseline
Heroin used years vs
MTD dose IL-8 TGF-β1 BDNF
Spearman r 0.203 -0.083 -0.212 -0.255
95% confidence interval
0.003 to 0.388 -0.276 to
0.116
-0.396 to -
0.013
-0.430 to -
0.061
P value (two-
tailed)
0.0404 0.3988 0.0321 0.0087
26
MTD, methadone; transforming growth factor (TGF)-β1; A non-parametric analysis
(Chen et al., 2013)
Plasma cytokine, and brain-derived neurotrophic factor
baseline data Heroin-dependent Patients p-value
Healthy Controls
MTD+Placebo MTD+Mem
n = 72 n = 57 n = 58
Gender (F/M) 10/62 10/47 10/48 0.817
Age (years) 31.64 ± 0.72 37.53 ± 0.93*** 37.24 ± 0.94*** < 0.0001
Heroin use (years) - 7.49 ± 0.49 8.36 ± 0.97 0.492
MTD dose (mg) - 36.23 ± 2.96 36.18 ± 2.70 0.991
Plasam TNF- (pg/mL) 1.57 ± 0.20 3.74 ± 0.47*** 3.62 ± 0.34*** < 0.0001
Plasma CRP (ng/mL) 1.66 ± 0.17 4.38 ± 0.44*** 3.60 ± 0.38*** < 0.0001
Plasma IL1- (pg/mL) 0.54 ± 0.09 1.42 ± 0.28** 1.97 ± 0.27*** < 0.0001
Plasma IL-6 (pg/mL) 1.23 ± 0.13 2.47 ± 0.35** 2.42 ± 0.28** 0.0004
Plasma IL-8 (pg/mL) 1.38 ± 0.28 4.66 ± 0.56** 6.53 ± 1.24*** < 0.0001
Plasma TGF-1 (ng/mL) 32.27± 2.0 24.16 ± 2.22** 23.02 ± 2.00** 0.0023
Plasma BDNF (ng/mL) 20.0 0 ± 1.09 11.40 ± 1.18*** 9.55 ± 0.83*** < 0.0001
27Mem, memantine; MTD, methadone; TGF, transforming growth factor One-way ANOVA for comparing cytokines and BDNF; age was used as a covariate.
(Chen et al., submitted 2013)
Results
After the 12-week treatment, compared with
baseline
•MTD (methadone) +Placebo group
– Increasing percentage of MTD dose after 4-week
•MTD+MM (memantine) group
– No change in MTD dosage
28(Chen et al., submitted 2013)
Heroin dependence treatment Methadone + Memantine (5 mg/placebo)
29(Chen et al., 2012)
Results
After the 12-week treatment, compared with both groups at baseline
•MTD with Placebo group
– No change in TNF- and IL-6, and BDNF levels
•MTD+MM group
– Decreasing TNF-, , IL-1β, IL-6 and IL-8 levels
– Increased tendency in BDNF level
30
(Chen et al., submitted, 2013)
Heroin dependence treatment Methadone + Memantine (5 mg/placebo)
31(Chen et al., 2012)
Heroin dependence treatment Methadone + Memantine (5 mg/placebo)
32(Chen et al., 2012)
Comments
• Longer heroin use (including MTD) increasing
inflammation and neurotrophic dysfunction.
• MTD with memantine treatment decreasing MTD-
induced inflammation and neurotrophic dysfunction
• MM inhibiting the tolerance for MTD
• MM decreasing cytokines & increasing BDNF levels
33
Comments
• Low dose Memantine– 5 mg/day of MM plasma level 10-50 ng/ml (0.05-0.2 M)
– No effect in NMDA receptor antagonist (IC50: 2-3 M)
(Parsons et al. 1999)
– Effective in heroin dependence treatment
– Benefit in neuron protect & decreasing neurodegeneration
34
Conclusions
• Over inflammation correlation with neurodegeneration, heroin
dependence & mental illness
• Treatment symptoms and treatment progress
• Regulation autoimmune & neuron (cell) protection or genesis,
benefits from central to peripheral
• New effective drugs & the novel treatment model breaking
through the difficulty of new drugs development
• Inhibiting the tolerance of heroin dependence, one of important factors
of substance dependence 35
Future Studies
• Treatment neuronal (cell) degeneration and developing
novel treatment in animal and human
• Developing related gene with the treatment effects
& predicted treatment response in central and
peripheral diseases
36
Acknowledgement
• Professor Jau-Shyong Hong, PhD.• Professor Pao-Luh Tao, PhD.• Hung-Ming Wu, MD. PhD.• Shiou-Lan Chen, PhD.• Shih-Heng Chen, PhD.• Chun-Hsien, Chu, PhD.• Kuei-Ying Hsu, MS.• Chen-Lin Wang, MS.• Yu-Ting Hung, BD.• Mei-Chun Wen, BD.• En-Jhen Chang, BD.
37
Thank you38
39
Potential beneficial effects of anti-inflammation-related drugs
• Addiction – Opiate abuse– Alcohol abuse – Smoking – Compulsive eating
disorder
• CNS diseases– Bipolar disorders– Depression– Schizophrenia– Alzheimer’s dis.– Brain ischemia – Parkinson’s dis.– MS – Spinal injury
• Peripheral diseases– Asthma– Arthritis – Arteriosclerosis– Cancer– Diabetes – Heart attack– Hepatitis – Inflammatory pain– Crohn’s dis. – Lupus – Sepsis
(endotoxemia)
40
Human peripheral effect
41
The lipid-rich atherosclerotic lesions were
identified with Oil-Red-O staining.
Dextromethorphan (DM) decreases high lipid diet-induced atherosclerotic lesion formation in apo-E-deficient mice
PBS 5 10 20 400
5
10
15
20
25
* *
*
DM (mg/kg)
Le
sio
n a
rea
(%
)
Control DM(10mg/kg)
DM(20 mg/kg) DM(40 mg/kg)
(Liu et al. 2009)
42
6.0
7.0
8.0
9.0
5.0
4.0
3.0
Placebo
DM
*
†
‡
0 3 6Time (months) after DM (60 mg/tablet, bid)
Flo
w m
edia
ted
dil
ata
tio
n r
atio
Clinical trial of dextromethorphan (DM) in heavy smokers
CR
P l
evel
s (m
g/d
l )
Time (months) after DM (60 mg/tablet, bid)
1
2
3
45
6
7
8
9
10
0 1 2 3 6
*
*
Placebo
DM
* *
Blood flow-mediated dilatation ratio C-reactive protein (CRP)
(Liu et al.)
43
Clinical trial of naltrexone in alcoholics
44(Chen et al., 2012)
Neurotrophic and neuroprotective effects of memantine
H.M. WU, H.L. CHEN, N.S. TZENG
J.S. HONG, R.B. LU* (2009)
45
Memantine has neurotrophic and neuroprotective effects to dopaminergic neurons
and against LPS-induced neurotoxicity46(Wu et al., 2009)
The neurotrophic effect of memantine is astrocyte-dependent.
47(Wu et al., 2009)
Memantine decreases the levels of pro-inflammatory factors induced by LPS. 48
(Wu et al., 2009)
Memantine has independent neuroprotective effects on LPS-induced
neurotoxcity.
49(Wu et al., 2009)
Memantine attenuates LPS-induced morphological activation of
microglia. 50(Wu et al., 2009)
In Summary
Pro-inflammatory Factors
Reactive Microgliosis
(Self-propelling)
Microglia
Neurons Trophic
factors:(GDNF, BDNF,
NGF)Neurogenesis
Astroglia(1)
(2)
(-)
Anti-inflammat
ion
Neuro-protection
Neuronalgenesis
(+)
51
Plasma Cytokine
52(Chen et al., 2012)